US Uncertainty Weighs on IPO Market While UK Innovation Could Benefit
Life Sciences Practice Co-chair William Hicks was featured in Pharmaceutical Technology following his participation as a panelist at the OBN BioTrinity 2025 conference in London, which focused on how US uncertainty is impacting the biopharma environment.
During the panel, Bill noted that although biopharma IPO activity rebounded in 2024, investor confidence is being tested again in 2025 due to President Trump’s recent tariff proposals and cuts to federal healthcare agencies.
Related to how companies should cope with the current market uncertainty, Bill suggests, “Waiting for the ideal market to come back, that’s not necessarily a strategy. Create your own opportunity.”
Source